community-acquired pneumonia

in review 6 min read Updated 2026-10-18
community-acquired pneumonia

PSI (ATS/IDSA preferred) or CURB-65 guides site of care. Ward CAP: β-lactam + macrolide or respiratory fluoroquinolone (ATS/IDSA 2019 — the exam answer); β-lactam monotherapy is an evidence-based alternative for non-severe CAP without Legionella risk (CAP-START (2015)) and common Canadian stewardship practice. ICU: β-lactam + macrolide (or β-lactam + respiratory fluoroquinolone) — never fluoroquinolone monotherapy. Most penicillin-allergic patients can still receive ceftriaxone. 5 days standard; 3 days if stable at day 3 on the ward (PTC (2021)).

CAP empiric antibiotics — ward admission
  • first-line (ATS/IDSA): ceftriaxone 1–2 g IV q24h + azithromycin 500 mg IV/PO q24h
  • non-severe, no Legionella risk: ceftriaxone alone acceptable (CAP-START)
  • always add azithromycin if CURB-65 ≥3, ICU/step-down, Legionella risk, or worsening
  • if β-lactams must be avoided (SCAR, serum sickness, AIN, haemolysis): levofloxacin 750 mg IV/PO q24h — see penicillin allergy
  • if prior respiratory MRSA: add vancomycin; stop if MRSA nasal swab and cultures negative
  • if prior respiratory Pseudomonas: piperacillin-tazobactam 4.5 g IV q6h instead of ceftriaxone
  • influenza season: influenza/COVID PCR → oseltamivir 75 mg PO BID if influenza positive
  • PO step-down when clinically stable: cefuroxime 500 mg PO BID or amoxicillin-clavulanate 875/125 mg PO BID
  • duration: 5 days (3 if stable at day 3; 7 if not yet stable at day 5)
local antibiogram

Macrolide resistance in S. pneumoniae varies between Canadian centres — outpatient macrolide monotherapy only where resistance is <25%.


severity assessment

CURB-65

criterionpoints
Confusion (AMT ≤8 or new disorientation)1
Urea >7 mmol/L1
Respiratory rate ≥30/min1
Blood pressure: SBP <90 or DBP ≤60 mmHg1
age ≥651
scoredisposition
0–1outpatient (mortality <3%)
2short-stay / ward admission
3–5ward or ICU (mortality 15–40%)

ATS/IDSA 2019 prefers PSI (Pneumonia Severity Index) over CURB-65 for site-of-care decisions — PSI class I–II → outpatient; CRB-65 (no urea; ≥2 → consider admission) is the bedside/clinic shortcut.

Severe CAP (ATS/IDSA) — 1 major or ≥3 minor → ICU/step-down:

  • major: invasive ventilation; septic shock needing vasopressors
  • minor: RR ≥30; PaO₂/FiO₂ ≤250; multilobar infiltrates; confusion; urea ≥7 mmol/L; WBC <4 × 10⁹/L; platelets <100 × 10⁹/L; temperature <36 °C; hypotension needing aggressive fluids

CURB-65 underestimates severity in young patients — apply minor criteria alongside.


workup in admitted patients

  • blood + sputum cultures: severe CAP, or prior MRSA/Pseudomonas — not routine in non-severe CAP
  • Legionella urinary antigen: severe CAP or epidemiological risk (detects serogroup 1 only, ~70% of cases → negative result + fitting syndrome: keep macrolide cover)
  • pneumococcal urinary antigen: severe CAP
  • influenza/COVID PCR when circulating — treat influenza-positive inpatients with oseltamivir regardless of symptom duration
  • MRSA nasal PCR: high negative predictive value → stop empiric vancomycin if negative
  • procalcitonin: does not decide whether to start antibiotics in radiographic CAP; <0.25 µg/L favours viral but does not exclude bacterial CAP in the acutely ill

empiric therapy by setting

outpatient — no comorbidities

  • amoxicillin 1 g PO TID × 5 days
  • alternative: doxycycline 100 mg PO BID × 5 days
  • azithromycin 500 mg day 1 → 250 mg days 2–5 only if local pneumococcal macrolide resistance <25%

outpatient — with comorbidities

Comorbidities = chronic heart, lung, liver, or renal disease; diabetes; alcohol use disorder; malignancy; asplenia.

  • amoxicillin-clavulanate 875/125 mg PO BID (or cefuroxime 500 mg PO BID) + azithromycin or doxycycline
  • or levofloxacin 750 mg PO daily (or moxifloxacin 400 mg PO daily)

inpatient — ward (non-severe)

  • ATS/IDSA 2019: β-lactam (ceftriaxone, ampicillin-sulbactam) + macrolide, or respiratory fluoroquinolone monotherapy
  • β-lactam monotherapy for non-severe CAP — CAP-START (2015): no difference in 90-day mortality vs β-lactam + macrolide; adopted by many Canadian stewardship programmes
  • add azithromycin if Legionella risk: stagnant/aerosolised water exposure, institutional outbreak, June–October; suggestive features — confusion, diarrhoea, hyponatraemia, transaminitis, hypophosphataemia
  • respiratory fluoroquinolone only when ceftriaxone cannot be used

inpatient — ICU

  • ceftriaxone 2 g IV q24h + azithromycin 500 mg IV q24h, or ceftriaxone + levofloxacin 750 mg IV q24h
  • never fluoroquinolone monotherapy
  • Pseudomonas/MRSA cover only with prior respiratory isolation of that organism, or hospitalisation + IV antibiotics within 90 days (ATS/IDSA) — not for “HCAP” factors (dialysis, nursing home, structural lung disease) alone
    • Pseudomonas: piperacillin-tazobactam 4.5 g IV q6h (or cefepime 2 g IV q8h) in place of ceftriaxone, still + azithromycin or levofloxacin for atypical cover
    • MRSA: add vancomycin — de-escalate at 48 h if nasal PCR and cultures negative

suspected macroaspiration

  • most is chemical pneumonitis → if rapid improvement, stop antibiotics and observe
  • ceftriaxone covers oral anaerobes adequately — no added metronidazole or clindamycin (Bai, CHEST. 2024: extended anaerobic cover → no mortality benefit, more C. difficile)
  • dedicated anaerobic cover only for lung abscess or empyema

penicillin allergy

  • no shared side chain between penicillins and ceftriaxone → ceftriaxone can be given after most penicillin reactions, including hives and anaphylaxis (Sunnybrook excludes near-fatal reactions within 10 years)
  • penicillin “allergy” that was GI upset or remote rash → standard β-lactam regimen, not a fluoroquinolone
  • avoid all β-lactams only after SCAR (SJS/TEN, DRESS, AGEP), serum sickness, AIN, or haemolytic anaemia → levofloxacin 750 mg
  • β-lactams contraindicated + ICU: levofloxacin + vancomycin if MRSA risk; aztreonam IV is Special Access Programme only in Canada
  • de-labelling (PEN-FAST, direct oral challenge): see penicillin allergy

duration

settingduration
outpatient5 days
ward (non-severe)5 days; 3 days if stable at day 3 — PTC (2021): non-inferior to 8 days
not yet stable at day 57 days
ICU / severe7 days (PTC excluded ICU)
confirmed Legionella≥7 days
Mycoplasma/Chlamydophilaazithromycin 500 mg × 3 days sufficient
empyema / abscess2–6 weeks, guided by drainage and imaging

Clinical stability (all required before stopping): T ≤37.8 °C, HR ≤100, RR ≤24, SBP ≥90, SpO₂ ≥90% on room air, normal mental status, tolerating PO. The same criteria trigger IV → PO switch.


adjunctive corticosteroids

  • CAPE COD (2023): severe CAP in ICU (ventilated, or HFNO/NIV with FiO₂ ≥50% and PaO₂/FiO₂ <300, or PSI >130) → hydrocortisone 200 mg/day × 4 days, then taper for 8 days total if improving (14 days if not); 28-day mortality 6.2% vs 11.9% (NNT ~18)
  • excluded septic shock and influenza — do not extrapolate to either
  • ESCAPe (2022): methylprednisolone 40 mg/day — no significant mortality benefit
  • SCCM 2024 focused update: suggests corticosteroids for severe CAP; not for non-severe CAP
  • watch hyperglycaemia and superinfection

when to broaden

  • no improvement by 48–72 h → repeat cultures, CT chest (abscess? empyema? alternative diagnosis?)
  • parapneumonic effusion >1 cm → diagnostic thoracentesis (pH, glucose, LDH, Gram stain, culture)
  • complicated parapneumonic effusion or empyema → chest tube + extended antibiotics

Prepared 2026-10-18. Not yet verified — check every number against the sources.

Key references

+5 more sources

Suggest a correction community-acquired pneumonia